CORRECTION article

Front. Med., 17 February 2022

Sec. Gastroenterology

Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.862010

Corrigendum: LncRNA MSC-AS1 Is a Diagnostic Biomarker and Predicts Poor Prognosis in Patients With Gastric Cancer by Integrated Bioinformatics Analysis

  • 1. Department of General Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

  • 2. Clinical Laboratory, The Children's Hospital of Henan Province, Zhengzhou Children's Hospital, The Affiliated Children Hospital of Zhengzhou University, Zhengzhou, China

Article metrics

View details

1,2k

Views

709

Downloads

Shuaibing Lu was not listed as a co-first author in the published article. The corrected author list appears below.

Wei Yang1†, Fusheng Ge1†, Shuaibing Lu1†, Zhiming Shan2, Liangqun Peng1, Junhui Chai1, Hongxing Liu1, Baodong Li1, Zhandong Zhang1, Jinxi Huang1, Yawei Hua1* and Yonglei Zhang1*

In the published article, there was an error in affiliation 1. Instead of “Department of General Surgery, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China,” it should be “Department of General Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

lncRNA MSC-AS1, prognosis, gastric cancer, bioinformatics, biomarker

Citation

Yang W, Ge F, Lu S, Shan Z, Peng L, Chai J, Liu H, Li B, Zhang Z, Huang J, Hua Y and Zhang Y (2022) Corrigendum: LncRNA MSC-AS1 Is a Diagnostic Biomarker and Predicts Poor Prognosis in Patients With Gastric Cancer by Integrated Bioinformatics Analysis. Front. Med. 9:862010. doi: 10.3389/fmed.2022.862010

Received

25 January 2022

Accepted

27 January 2022

Published

17 February 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

9 - 2022

Updates

Copyright

*Correspondence: Yawei Hua Yonglei Zhang

†These authors have contributed equally to this work

This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics